Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Fibrinogen Protein Levels May Help Predict Exacerbation Outcomes

Levels of the protein fibrinogen in the blood can be used to assess inflammation and the risk of non-invasive ventilation failure during acute exacerbations in people with chronic obstructive pulmonary disease (COPD), according to a new study. Fibrinogen is an inflammation-associated protein that is known as a biomarker for…

DSP Gene in COPD May Limit Ability of Lung Cells to Repair Injuries

Using the gene-editing technology CRISPR, a team led by scientists at Boston University has shown that several genes previously associated with susceptibility to chronic obstructive pulmonary disease (COPD) affect the development of lung cells. The results specifically suggest that, in COPD, increased expression or activity of a gene called…

New Soft, Wearable Stethoscope May Make It Easier to Detect COPD

Scientists have developed a soft, wearable stethoscope that could make it easier to detect lung abnormalities that are indicative of chronic obstructive pulmonary disease (COPD). The new device was described in a study, “Fully portable continuous real-time auscultation with a soft wearable stethoscope designed for automated…

FDA Approves Generic Version of Brovana for Long-term Treatment

The U.S. Food and Drug Administration (FDA) has approved Lupin Limited’s generic form of Brovana (arformoterol tartrate) for treating bronchoconstriction in people with chronic obstructive pulmonary disease (COPD). Like the name-brand medicine sold by Sunovion Pharmaceuticals, the new generic is indicated for long-term maintenance treatment, according to…